Neurofila-ments and glial fibrillary acidic protein (GFAP) have emerged as promising candidates for examining disease pathophysiology in neurological conditions, such as multiple sclerosis (MS), Alzheimer disease, Parkinson’s disease, and others [1,2,3,4,5]. The gene discussed is GFAP; the disease is myeloid sarcoma.